Madsen Julia sold $532K of STE

Madsen Julia (Sr. VP and GM, Life Sciences) sold 2,046 shares of STERIS plc (STE) at $260.00 ($0.53M total) on 2026-11-13.

Original reporting
SEC EDGAR · Madsen Julia
Published Nov 17, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

Insider open-market sales are typically low-signal unless unusually large, paired with other negative disclosures, or part of a broader pattern; this filing alone does not indicate a fundamental change.

02

Market read

Traders may note the insider sale for sentiment, but there is no new company catalyst or guidance change in the text.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, taxes, or planned compensation exercises, limiting inference.

Relevance 5/10Novelty 3/10Timing: filed 2026-11-17, transaction dated 2026-11-13

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc (STE).

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

SEC Form 4 shows STERIS Sr. VP and GM Life Sciences Julia Madsen sold 2,046 shares at $260 on 2026-11-13.

Expected impact

Likely minimal near-term impact, though some traders may briefly weigh insider-selling optics.

Evidence & confidence

The filing is a Form 4 insider sale, not a guidance, contract, or regulatory event. The disclosed size is moderate and the article provides no additional company-specific catalyst.

Market effects

Insider-sale optics can marginally affect sentiment for medical/life-sciences tools names, but no sector-wide signal is provided.

No direct regional market linkage beyond general US-listed sentiment.

No global catalyst; event is company-specific insider transaction.

Counterpoint

The sale may be purely personal liquidity or diversification, especially since the filing does not indicate any operational or strategic change by the company.

Key entities

  • STERIS plc

    US-listed medical/life-sciences company subject of the Form 4 insider sale disclosure.

  • Julia Madsen

    Sr. VP and GM, Life Sciences, reported an open-market sale of STE shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEMedAI 8/10

STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland and a wholly-owned subsidiary of STERIS plc, a public…

STERIS plc (STE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “C

$STEMed

What STERIS (STE) Said on Its Q2 Earnings Call

STERIS (STE) reported Q2 adjusted EBIT margin up 150 bps to 24.6%, with EPS growth of 13% excluding refunds. Life Sciences revenue rose 18%, leading to an increased full-year growth forecast of 9-10%. AST segment revenue grew 5%, but its forecast was lowered to 6-7%. The company announced a $45M restructuring plan and expects its Xodus Medical acquisition to boost revenue and margins.

$STEMed

Steris PLC (STE) (Q2 2027) Earnings Call Highlights: Revenue Climbs 9%

STERIS PLC reported Q2 2027 revenue up 9%, but EBIT margins declined in both Healthcare and AST segments due to inflation and other factors. AST revenue growth guidance was lowered. Free cash flow decreased. A $45M restructuring plan was announced. CEO Dan Carestio discussed growth opportunities, including the Xodus Medical acquisition, and addressed margin pressures and market dynamics.

$STEHighAI 8/10

STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.

$CATMedAI 8/10

Caterpillar's $1B Sanford Plant Fuels Raleigh-Durham Growth

Caterpillar plans to invest $1B in a North Carolina plant, expanding manufacturing capacity. The project is part of a broader industrial surge in Raleigh-Durham, with increased leasing activity and construction. Other companies, including AbbVie, Siemens, and Forge Nano, are also investing in the region. Research Triangle Park is diversifying with mixed-use and residential developments.